The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

Cited by (614)

Items 401–500 of 614

1. The Detection of Exosomal PD-L1 in Peripheral Blood
   Rui Wang, Yanjia Yang, Jiajun Huang, Yandan Yao · 2023 · Methods in molecular biology
2. Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer
   Xingyu Li, Yanyan Zhang, Cheng Zhu, Wentao Xu, Xiaolei Hu, Domingo Antonio Sánchez Martínez, José Luis Alonso Romero, Ming Yan, Ying Dai, Hua Wang · 2024 · BMC Women s Health
3. Association of a PD-L2 Gene Polymorphism with Chronic Lymphatic Filariasis in a South Indian Cohort
   Gopinath Venugopal, Noëlle Louise O’Regan, Subash Babu, Ralf R. Schumann, Aparna Srikantam, Roswitha Merle, Susanne Hartmann, Svenja Steinfelder · 2018 · American Journal of Tropical Medicine and Hygiene
4. Different Triple-Negative Breast Cancer Tumor Cell Lysates (TCLs) Induce Discrepant Anti-Tumor Immunity by PD1/PDL-1 Interaction
   Bohan Dong, Yuanyuan Ding, Qianwu Huang, Xiaoxiang Guan · 2019 · Medical Science Monitor
5. T-Cell Engagers Based Bioassay for Evaluation of PD-1/PD-L1 Inhibitors Activity
   A. N. Doronin, Aleksandr Gordeev, A. E. Kozlov, Ya. A. Smirnova, Maria Puchkova, Viktoria M. Ekimova, Yu. I. Basovskiy, Valery V. Solovyev · 2019 · Biochemistry (Moscow)
6. Targeting IL-27 and/or IL-10 in Experimental Murine Visceral Leishmaniasis
   Henry W. Murray · 2020 · American Journal of Tropical Medicine and Hygiene
7. Parameters of Tumor Microenvironment Determine Effectiveness of Anti-PD-1/PD-L1 Therapy
   Л. А. Таширева, Dariya T. Muravyova, Natalya O. Popova, Victor E. Goldberg, Sergey Vladimirovich Vtorushin, Перельмутер Владимир Михайлович · 2021 · Biochemistry (Moscow)
8. Investigation of Unprecedented Sites and Proposition of New Ligands for Programmed Cell Death Protein I through Molecular Dynamics with Probes and Virtual Screening
   Luca Andrade, Aline Albuquerque, Andrielly Henriques Santos-Costa, D. B. VASCONCELOS, Wilson Savino, G. Sartori, João Hermínio Martins da Silva · 2022 · Journal of Chemical Information and Modeling
9. VSTM2A reverses immunosuppression in colorectal cancer by antagonizing the PD-L1/PD-1 interaction
   Yujuan Dong, Jiaxun Jade Liu, Yunfei Zhou, Wei Kang, Shanglin Li, Alvin H.K. Cheung, Yi Hu, Rui Jin Liao, Nathalie Wong, Chi Chun Wong et al. · 2024 · Molecular Therapy
10. PD-1-dependent therapeutic effect of Trichinella spiralis cystatin on myocardial infarction in a mice model
    Weixiao Zhang, Wenhui Yin, Hongtao Wang, Lingqin Wu, Chang Li, Xinyu Peng, Xiang Li, Kaibo Jiang, Huiqi Yang, Chenyue Dang et al. · 2025 · Parasites & Vectors
11. Clinical Significance of Negative Costimulatory Molecule PD-1/PD-L1 on Peripheral Blood Regulatory T Cell Levels among Patients with Pulmonary Tuberculosis
    Chenchen Yang, Fanchao Dai, Rexiti Pulati, Yan Jiao, Qian Xu · 2022 · Journal of Tropical Medicine
12. Integrated Analysis of C16orf54 as a Potential Prognostic, Diagnostic, and Immune Marker across Pan-Cancer
    Xinna Du, Wei Xia, Weiping Fan, Xuan Shen, Hongyan Wu, Hu Zhang · 2022 · Disease Markers
13. [Research Advances of Immunotherapy of Exosome PD-L1 in Non-small Cell Lung Cancer].
    Na Wang, Xia Song · 2022 · PubMed Central
14. Immune Checkpoint Molecules and Maternal–Fetal Immunity
    Sloane A. Mebane, Jie H. S. Zhou, Sehee Choi, Danny Joseph Schust · 2024 · Current Obstetrics and Gynecology Reports
15. A Myeloid-Specific Lack of IL-4Rα Prevents the Development of Alternatively Activated Macrophages and Enhances Immunity to Experimental Cysticercosis
    Jonadab E. Olguín, Edmundo Corano-Arredondo, Victoria Hernández-Gómez, Irma Rivera-Montoya, Mario Alberto Tonathiu Rodriguez-Hernandez, Itzel Medina-Andrade, Berenice Arendse, Frank Brombacher, Luis Ignacio Terrazas · 2024 · Pathogens
16. Unraveling impact and potential mechanisms of baseline pain on efficacy of immunotherapy in lung cancer patients: a retrospective and bioinformatic analysis
    Zexin Zhang, Wenjie Zhao, Chang Lv, Zexia Wu, Wenhao Liu, Xuesong Chang, Yaya Yu, Zhenzhen Xiao, Yihan He, Haibo Zhang · 2024 · Frontiers in Immunology
17. Anoctamin 9 determines Ca2+ signals during activation of T-lymphocytes
    Rainer Schreiber, Jiraporn Ousingsawat, Karl Kunzelmann · 2025 · Frontiers in Immunology
18. Recently approved treatment options for patients with metastatic triple-negative and HER2-neu-positive breast cancer
    Sayed Reshad Ghafouri, Suvarna L Guvvala, Catherine Jones, Alexander V. Philipovskiy · 2022 · Journal of Investigative Medicine
19. Flow-Cytometry Intracellular Detection and Quantification of HIV1 p24 Antigen and Immunocheckpoint Molecules in T Cells among HIV/AIDS Patients
    Belay Tessema, Andreas Boldt, Brigitte König, Melanie Maier, Ulrich Sack · 2022 · HIV/AIDS - Research and Palliative Care
20. Local Delivery of Immunomodulatory Antibodies for Gastrointestinal Tumors
    Noelia Silva-Pilipich, Ángela Covo-Vergara, Cristian Smerdou · 2023 · Cancers
21. Associations between plasma metabolism-associated proteins and future development of giant cell arteritis: results from a prospective study
    Karin Wadström, L. Jacobsson, Aladdin J Mohammad, Kenneth J. Warrington, Eric L. Matteson, Magnus E. Jakobsson, Carl Turesson · 2024 · Lara D. Veeken
22. Exploring Costimulatory Blockade-Based Immunologic Strategies in Transplantation: Are They a Promising Immunomodulatory Approach for Organ and Vascularized Composite Allotransplantation?
    Andreea Grosu-Bularda, Florin-Vlad Hodea, Dragoş Zamfirescu, Alexandru Stoian, Răzvan Nicolae Teodoreanu, Ioan Lascăr, Cristian-Sorin Hariga · 2024 · Journal of Personalized Medicine
23. Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach
    Michail Nikolaou, Georgios Nikolaou, Antonia Digklia, Christos Pontas, Nikolaos Tsoukalas, George Kyrgias, Maria Tolia · 2019 · Integrative Cancer Therapies
24. A mechanistic quantitative systems pharmacology model platform for translational efficacy evaluation and checkpoint combination design of bispecific immuno-modulatory antibodies
    Yiyang Xu, Siyuan Yang, Qi Rao, Yuan Gao, Guanyue Zhou, Dongmei Zhao, Xiaolu Shi, Yi Chai, Chen Zhao · 2025 · Frontiers in Pharmacology
25. Using extension‐based mRNA display to design antibody‐like proteinogenic peptides for human PD ‐ L1
    Justin N. Ong, Brian J. Grindel, Scott A. Rankin, Sarah H. Naylon, Anupallavi Srinivasamani, Guillaume J Trusz, Xiaowen Liang, Md Nasir Uddin, Lauren Fuller, Michael A. Curran et al. · 2025 · Protein Science
26. Safety and Efficacy of Immune Checkpoint Inhibitors in Children and Young Adults with Haematological Malignancies: Review and Future Perspectives
    Eleni Tsotridou, Eleni Vasileiou, Elpis Mantadakis, Athanasios Tragiannidis · 2021 · Cardiovascular & Hematological Agents in Medicinal Chemistry
27. Soluble Programmed Death-Ligand 1 (sPD-L1) as a Promising Marker for Head and Neck Squamous Cell Carcinoma: Correlations With Clinical and Demographic Characteristics
    Amani Ahmed Alrehaili, Amal Fathi Gharib, Abdulraheem Ali Almalki, Ahmed Alghamdi, Nahed Mohammed Hawsawi, Maha Mahfouz Bakhuraysah, Hayaa M. Alhuthali, Rasha L. Etewa, Wael H. Elsawy · 2023 · Cureus
28. PD-L1 DNA aptamers isolated from agarose-bead SELEX
    Muhammad Najmi Mohd Nazri, Nur Amira Khairil Anwar, Nur Fatihah Mohd Zaidi, Khairul Mohd Fadzli Mustaffa, Noor Fatmawati Mokhtar · 2024 · Bioorganic & Medicinal Chemistry Letters
29. Immune-related adverse events correlate with the clinical efficacy in advanced Non-Small-Cell Lung Cancer patients treated with PD-1 inhibitors combination therapy
    Xiaowan Xie, Yuhao Li, Qiaomei Lv, Wei Wang, Wenbo Ding, Yuanyuan Li · 2024 · BMC Cancer
30. Bta-miR-93 regulates the maternal-fetal tolerance in dairy cows via promoting Programmed Cell Death Ligand 1 mediated M2 macrophage polarization
    Cheng Yang, Xinyu Feng, Yingfang Guo, Aftab Shaukat, Zhimin Wu, Yu Chen, Meng Lu, Ganzhen Deng · 2025 · Biology of Reproduction
31. CiTE antibody for AML
    Michael P. Rettig, John F. DiPersio · 2018 · Blood
32. Significance of metastatic topography for the immunotherapy of cutaneous and ocular melanomas
    Sorin Săftescu, Mihnea Munteanu, Dorel Ionel Popovici, Radu Dragomir, Alina Gabriela Negru, Cristina Pac, Serban Mircea Negru · 2020 · Romanian Journal of Ophthalmology
33. PD-L1 and CD8-Tumor-Infiltrating Lymphocytes Expression in Laryngeal Squamous Cell Carcinoma
    Oana Cojocaru, Mariana Aşchie, Antonela-Anca Nicolau, Burlacu Ionuț, Manuela Enciu, Gabriela Izabela Bălţătescu · 2020 · Ars medica tomitana
34. Dostarlimab for Endometrial Cancer: A Comprehensive Review of Clinical Outcomes
    Raviteja S Kanavi, Akash Chathamvelli, Deepjyoti Saikia · 2023 · International Journal of Science and Healthcare Research
35. Tumor Suppression by PD-1/PD-L1 Interaction Blockage in Mice Model
    Shima Salehi, Hajarossadat Ghaderi, Mahdi Habibi‐Anbouhi, Alireza Shoari, Ayda Hassanzadeh Eskafi, Alireza Sabouri, Mohammad Hosseininejad-Chafi, Arghavan Ashja Ardalan, Behzad Ramezani, Fatemeh Kazemi‐Lomedasht et al. · 2023 · Iranian journal of pharmaceutical research
36. Case report: Fatal hemoptysis after effective treatment with tislelizumab and anlotinib in pulmonary sarcomatoid carcinoma
    Chen-Wei Pu, Yong-Fen Ma, Jingjing Peng, Zhen-Zhen Wang · 2024 · Frontiers in Oncology
37. Comprehensive Advanced Physicochemical Characterization and In Vitro Human Cell Culture Assessment of BMS-202: A Novel Inhibitor of Programmed Cell Death Ligand
    Hasham Shafi Sofi, Andrea J. Lora, Haley M. Donow, Sally E. Dickinson, Georg T. Wondrak, H.‐H. Sherry Chow, Clara N. Curiel‐Lewandrowski, Heidi M. Mansour · 2024 · Pharmaceutics
38. Melatonin, programmed death ligand-1, programmed death ligand-1, and cancer: imagine beyond the future?
    José Maria Soares, İlker Şengül, Demet Şengül · 2025 · Revista da Associação Médica Brasileira
39. CD4+T cell specific B7-H1 selectively inhibits proliferation of naïve T cells and Th17 differentiation in experimental autoimmune encephalomyelitis
    Shengjia Shi, Meiling Ding, Lijuan Wang, Jieheng Wu, Donghui Han, Guoxu Zheng, Zhangyan Guo, Wenjin Xi, Wei-Jun Qin, Angang Yang et al. · 2017 · Oncotarget
40. Updates to Clinical Information on Anticancer Immunotherapy
    Eunjoo Choi, Jae Wook Yang · 2018 · Korean Journal of Clinical Pharmacy
41. Alteration of Mesenchymal Stem Cells Isolated from Glioblastoma Multiforme under the Influence of Photodynamic Treatment
    Kalina D. Tumangelova-Yuzeir, Krasimir Minkin, Иван Ангелов, Ekaterina Ivanova‐Todorova, Ekaterina Krasimirova Kurteva, Georgi Vasilev, Jeliazko Iliev Arabadjiev, Petar Karazapryanov, Kaloyan Gabrovski, Lidia Zaharieva et al. · 2023 · Current Issues in Molecular Biology
42. Cancer research and innovation: conceptualising a persistent anomaly
    Yingyong Xu, Dimitri Gagliardi · 2023 · Innovation
43. Glycans on non-structural protein 1 prevent premature T-cell mediated dengue virus clearance
    Fakhriedzwan Idris, Justin S. G. Ooi, Donald Heng Rong Ting, Eunice Tze Xin Tan, Corrine Wan, Peter Imre Benke, Jan K. Marzinek, Jack M. Copping, Qin Hui Li, Lu Yi Ng et al. · 2025 · EMBO Molecular Medicine
44. Epigenetic therapy combined with radiotherapy reshapes tumor immune response
    Jianing Wang, Junbao Xu, Xiaoqing Ma, Qianqian Wang, Zhengchun Liu, Xuecheng Zhang, Yongqiang Wei, Shuai Wang, Chunjing Liang, Peiling Zhai · 2026 · Experimental and Molecular Pathology
45. Clinicopathologic implication of PD-L1 gene alteration in primary adrenal diffuse large B cell lymphoma
    Ki Rim Lee, Jiwon Koh, Yoon Kyung Jeon, Hyun Jung Kwon, Jeong‐Ok Lee, Jin Ho Paik · 2021 · Journal of Pathology and Translational Medicine
46. Role of Hemin in the Immune Response of T Follicular Helper Lymphocytes Expressing T-Cell Immunoreceptor with Immunoglobulin and Immunoreceptor Tyrosine-Based Inhibitory Domains, Programmed Cell Death-1, and Interleukin-21 in Allo-Auto Positive and Negative Thalassemia
    Betty Agustina Tambunan, I Dewa Gede Ugrasena, Aryati Aryati · 2023 · Journal of Blood Medicine
47. Multi-index comprehensive evaluation of the efficacy and response mechanism of immunotherapy in non-small cell lung cancer
    Jieqiong Fan, Tao Zhang · 2024 · Clinical & Translational Oncology
48. UBTF facilitates acute myeloid leukemia development and immune escape via PD-L1 regulation
    Chunxia Yang, Junzhao Wan, Yan Wang, Ying Yang, Yunsheng Ran, Fenli Zhang, Man Zhou, Ping Liu, Qian Kang, Dan Ma et al. · 2025 · International Immunopharmacology
49. Advancements and challenges in CAR T cell therapy for pediatric brain tumors: A review
    Yasmina Gaoual, Adam Mahyaoui, Lamyae Yachi, Mustapha Bouatia, Z Aliat, Younes Rahali · 2025 · Journal of Oncology Pharmacy Practice
50. YY1 expression and PD-1 regulation in CD8 T lymphocytes
    Roni Touboul, Benjamin Bonavida · 2021 · Elsevier eBooks
51. Cancer research driven by cutting-edge multi-disciplinary technologies
    Qunyan Lyu, Yukuan Feng, Rong Shi, Jing Wu, Weidong Han · 2020 · Chinese Science Bulletin (Chinese Version)
52. Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
    Bernard F. Hearon, Kyle N. Redelman, Georges C. Elhomsy, Dennis Frederic Moore · 2020 · Case Reports in Oncology
53. Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade
    John Moise, Jeevan J. Murthy, Dolma Dabir, Stephen Yu, Farah Kisto, Emily Herron, Sonikpreet Aulakh · 2022 · Immuno
54. Application of single cell multiomics points to changes in chromatin accessibility near calcitonin receptor like receptor and a possible role for adrenomedullin in the post-shock lung
    Brandon E. Armstead, Chung Sunny Lee, Yaping Chen, Runping Zhao, Chun‐Shiang Chung, Alger M. Fredericks, Sean F. Monaghan, Alfred Ayala · 2023 · Frontiers in Medicine
55. The relationship between PD-L1 and quiescence in melanocyte stem cell aging
    Joseph W. Palmer, Kyrene M. Villavicencio, Misgana I. Idris, Dominique Weddle, Fabian V. Filipp, NISC Comparative Sequencing Program, William J. Pavan, Melissa L. Harris · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
56. De-glycosylated non-structural protein 1 enhances dengue virus clearance by limiting PD-L1/PD-1 mediated T cell apoptosis
    Fakhriedzwan Idris, Donald Heng Rong Ting, Eunice Tze Xin Tan, Corrine Wan, Kuan Rong Chan, Peter Imre Benke, Jan K. Marzinek, Jack M. Copping, Qin Hui Li, Ian Walsh et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
57. Quantifying PD1 Saturation by PDL1 in Tumor Tissue Using a Novel RNA Aptamer-Based Assay
    Suresh Veeramani, Chaobo Yin, Nanmeng Yu, Kristen L. Coleman, Brian J. Smith, George J. Weiner · 2026 · International Journal of Molecular Sciences
58. A novel cuproptosis-related lncRNA prognostic signature for predicting treatment and immune environment of head and neck squamous cell carcinoma
    Changxiang Huan, Jiaxin Gao · 2022 · Mathematical Biosciences & Engineering
59. Study of Ridostin Pro and Poly(I:C) as adjuvants that enhance the immunogenicity of an antitumor vaccine
    А. V. Ponomarev, P. V. Tsarapaev, Maria A. Baryshnikova, Sokolova Za, A. A. Rudakova, M. V. Mironova, D. V. Gusev, G. M. Levagina, Е. Д. Даниленко, Vyacheslav S. Kosorukov · 2024 · Siberian Journal of Oncology
60. 1,25(OH) 2 D 3 -treated mouse bone marrow-derived dendritic cells alleviate autoimmune hepatitis in mice by improving TFR/TFH imbalance
    Juan Dai, Jianguo Song, Xueping Chen, Fei Ding, Ding Yanbo, Liang Ma, Liwen Zhang · 2024 · Immunopharmacology and Immunotoxicology
61. Immune сheckpoints in the context of external genital endometriosis
    A. S. Belevich, Maria Igorevna Yarmolinskaya, S. А. Selkov, Д. И. Соколов · 2024 · Medical Immunology (Russia)
62. Can NaCl predict or even enhance responses to immunotherapy in cancer?
    Jonas Saal, Michael Hölzel, Niklas Klümper · 2025 · European Journal of Cancer
63. Production and Functional Evaluation of Anti-PD-L1 scFv Antibodies in E. coli and HEK293 Expression Systems: A Comparative Study
    Naeimeh Roshanzamir, Zahra Shahosseini, Ziba Vaise Malekshahi, Jafar Aghajani, Babak Negahdari, Kayhan Azadmanesh · 2025 · Molecular Biology
64. Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
    Ignacio Melero, Josep M. Tabernero, Neeltje Steeghs, Debbie G. J. Robbrecht, Solange Peters, Naiyer A. Rizvi, Eileen Mary O'Reilly, Emiliano Calvo, Rikke Løvendahl Eefsen, Natasha B. Leighl et al. · 2025 · Clinical Cancer Research
65. Synergistic Mn‐MOF Activation of Pistol Ribozymes for Cancer Immunotherapy
    Ming Zhao, Shan Qiao, Jie Bai, George Zhang, Zhiqin Xi, Zhenzhen Li, Xuelin Zhan, Ying Zhang, Xiaotong Yu, Yao Chen et al. · 2026 · Advanced Science
66. Mucous Membrane Pemphigoid After Anti‐ PD ‐1 Therapy: Risk‐Stratified Management and Treatment Outcomes
    Serena Dienes, Negar Esfandiari, Steven D. Daveluy · 2026 · International Journal of Dermatology
67. Disrupting immune silence: Noncoding RNAs targeting the programmed cell death protein 1/programmed cell death ligand 1 axis in tumor immunity
    Chou-Yi Hsu, Ahmed M. Hjazi, Muath Suliman, Gunjan Singh, Vimal Arora, Akhrorova Shakhlo, Priya Priyadarshini Nayak, Abhayveer Singh, Hamza Fadhel Hamzah, Zahir Al-Khafaji · 2026 · Journal of Pharmacology and Experimental Therapeutics
68. The application of nanoparticle-mediated siRNA delivery systems in ovarian cancer
    Xueqian Qian, Yuan Yu, Yaning Zhang, Zemin Dou, Chengjin Gao, Yangyang Han · 2026 · Cancer Gene Therapy
69. A Case of Concurrent Autoimmune Thyroiditis and Adrenal Insufficiency Following Nivolumab Therapy for Advanced Renal Cell Carcinoma
    Gillian D Dooley, Henry Li, Ihunanya Agomuoh, Fahd Al-Saghir, Camelia Arsene · 2026 · Cureus
70. Reprogramming the tumor microenvironment via TFF3 targeting: a potential novel avenue to boost CAR-T cell therapy in solid tumors
    Arman Rahimi, Ghasem Solgi, Mehrnoush Safarzadeh, Pantea Mohammadi, Mohsen Rastegari‐Pouyani · 2026 · Cancer Gene Therapy
71. Exploring PDLIM2 as a prognostic biomarker and therapeutic target in lung adenocarcinoma
    Karam Ashouri, Fan Sun, Harris Benjamin Krause, Andrew Elliott, Stephen V. Liu, Patrick C. Ma, Balázs Halmos, Gutian Xiao, Ari VanderWalde, Jorge J. Nieva et al. · 2026 · British Journal of Cancer
72. Intrinsic and acquired cancer immunotherapy resistance
    Reem Saleh, Varun Sasidharan Nair, Salman M. Toor, Eyad Elkord · 2021 · Elsevier eBooks
73. Immune Checkpoint Inhibitors
    Keith C.K. Lau, R. Benson Weyant, Carlos Cervera · 2022 · Springer eBooks
74. Immunotherapy: Targeting Cancer Cells
    M. Vindhya, M. N. Ramesh Bharadwaj, Kanthesh Maheshwarappa Basalingappa, T.S. Gopenath, Ashok Gnanasekaran · 2023 · Biological and medical physics, biomedical engineering
75. Dual impact of radiation therapy on tumor-targeting immune responses
    Céline Mirjolet, Jérémy Baude, Lorenzo Galluzzi · 2023 · International review of cytology
76. Synthesis of some Sulfonamide Derivatives coupled with Salicylamide or Anisamide Scaffold as Potent PD-L1 Inhibitors and their Anti-proliferation Assay
    Nagwa M. Abdelazeem, Mohammad Alwahsh, Alaaeldin M F Galal, Shahd Talhouni, Lama Hamadneh, Atef G. Hanna · 2023 · Egyptian Journal of Chemistry
77. The administration of PD-1 and PD-L1 inhibitors in pediatric hematology: a literature review
    Aleksandra S. Paderina, Timur Teimurazovich Valiev · 2024 · Педиатрическая фармакология
78. The Functional Cancer Immunity Cycle
    Ann Hanna, Justin Micah Balko · 2024 · Cancer immunotherapy
79. A Novel Monoclonal Antibody against PD-1 for the Treatment of Viral Oncogene-Induced Tumors or Other Cancer
    Xu Xu, Shih-Long Yan, Yi‐Te Yo, Peiyu Chiang, Chan‐Yen Tsai, Lih‐Ling Lin, Albert Qin · 2024 · Cancers
80. The potential of nanosystems in disrupting adenosine signaling pathways for tumor immunotherapy
    Yutong Zhao, Jingqi Sun, Xiaoling Xu, Jin Su, Yongzhong Du · 2024 · Expert Opinion on Drug Delivery
81. Positivity Rate of PD-L1 Expression and Its Clinical Significance in Vulvar Cancer: A Systematic Review and Meta-Analysis
    Stefanos Flindris, Chrysoula Margioula‐Siarkou, Christos V. Chalitsios, Georgia Margioula‐Siarkou, Emmanouela-Aliki Almperi, Aristarchos Almperis, Effrosyni Styliara, Konstantinos Flindris, Minas E. Paschopoulos, Iordanis Navrozoglou et al. · 2025 · International Journal of Molecular Sciences
82. Can the co-localization of CD8+, PD-1, PD-L1 AND PD-L2 patterns provide guidance in clinical outcomes of patients with head and neck cutaneous squamous cell carcinoma?
    Gustavo Nunes Bento, André Bandiera de Oliveira Santos, Leandro Luongo Matos, William C. Faquin, Sara Isabel Pai, Cláudio Roberto Cernea · 2025 · Brazilian Journal of Otorhinolaryngology
83. Mending Broken Hearts
    Georges Makhoul, Kashif Khan, Renzo Cecere · 2018 · Elsevier eBooks
84. Does PD1/PDL1 Immunotherapy Require Patient Tumor Subgroup Pre-Analysis in the Era of Precision Medicine?
    Lucia Scarabel, Giuseppe Toffoli · 2018 · Journal of Molecular and Clinical Medicine
85. An Introduction to CAR Immunotherapy
    Mumtaz Yaseen Balkhi · 2019 · Elsevier eBooks
86. PROTECTION OF T-LYMPHOCYTES VIA PD-1 RECEPTOR: NEW MOLECULAR MECHANISM OF CANCER IMMUNOTHERAPY
    Sándor Szabó, & · 2019 · Proceedings of the Shevchenko Scientific Society Medical Sciences
87. [Role of programmed death-1 in viral infectious diseases].
    Fu-Ce Lu, Guangmin Nong · 2018 · PubMed Central
88. Lymph nodes may be a source for immunetherapy in gastric cancer
    P. P. ASSUMPÇÃO, Érika Thaiane Couto Canelas, Aline Cruz Ramos, Ana Karyssa Mendes Anaissi, João Felipe Acioli, Geraldo Ishak, Sidney Emanuel Batista dos Santos, Sâmia Demachki, Paulo Pimentel de Assumpção · 2020 · Oncotarget
89. Immunometabolism in haematopoietic stem cell transplantation and adoptive cellular therapies
    Erica Lynne Braverman, Gail Waltz, Craig Alan Byersdorfer · 2020 · Current Opinion in Hematology
90. Leishmania donovani
    Samar Habib, Manar Sobh Azab, Khaled Elmasry, Aya E. Handoussa · 2021 · Asian Pacific Journal of Tropical Medicine
91. PARADIGMS OF COVID-19 AND THE CYTOKINE THERAPY APPROACHES
    Muhammad Qasim Idrees, Alessandro Nutini, Ayesha Sohail · 2021 · Biomedical Engineering Applications Basis and Communications
92. Tumor immune tissue response to a solitary fibrous tumor treated with pazopanib
    Toshiaki Kawano, Takashi Hirano, Maki Fujinaga, Yoshinori Kadowaki, Takayuki Matsunaga, Kaori Tateyama, Yumi Kizu, Masashi Suzuki · 2021 · Clinical Case Reports
93. Checkpoint-Inhibitoren
    Peter Brossart, Viktor Grünwald, Sebastian Ochsenreither · 2021 · Springer Reference Medizin
94. Current Strategies Incorporating Immune Checkpoint Inhibitors for the Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancers
    Gianmarco Motta, Paolo Giovanni Vigneri · 2019 · Future Oncology
95. Nivolumab augments antitumor activity of invariant natural killer T cells
    Mami Negawa, Fumie Ihara, Shinichiro Motohashi · 2020
96. Galectin-1 upregulates IDO1 and PD-L1 and induces a tolerogenic tumor-associated macrophage phenotype
    Asha M. Rudjord-Levann, Zilu Ye, Lise Hafkenscheid, Sabrina Horn, Renske Wiegertjes, Mathias Ingemann Nielsen, Caroline Benedicte Kjærulff Mathiesen, Jesse Stoop, Sean R. Stowell, Per thor Straten et al. · 2022 · Research Square
97. Interleukin-6 and Interferon-gamma Ratio as a Predictor of Immune State and Viral Suppression in HIV-1 Infection
    Jude Emunyu, Collins Ankunda, Patrick Ssemugenze, Vivien Nabbanja, Angela Bakunda, John Bosco Muhanguzi, Samuel Wamutu, Barbara Nerima · 2024 · Research Square
98. Overview of Vaccine Strategies Against Epidermal Growth Factor Receptor in Brain Tumors
    Kristen A. Batich, Alexa N. Bramall, Carter M. Suryadevara, John Howard Sampson · 2018 · Elsevier eBooks
99. Molecular cloning, expression and characterization of Pekin duck programmed death-1
    Qingxia Yao, Karl P. Fischer, D. Lorne Tyrrell, Klaus S. Gutfreund · 2019 · Gene
100. New view on alcoholic liver disease - potential role of PD1/PDL-1 pathway in the disease pathogenesis
     Katarzyna Adamczyk, Beata Kasztelan‐Szczerbińska, Anna Rycyk, Halina Cichoż‐Lach · 2019 · Journal of Education Health and Sport